0.54 | 5.30%
| Price and Volume | |
|---|---|
| Recent Price | 10.73 |
| 52 Week High | 37.47 |
| 52 Week Low | 9.67 |
| Avg. Daily Vol. (Mil) | 1.96 |
| Beta (3 year) | 5.01 |
| Share Related Items | |
| Mkt Cap (Mil) | 701.69 |
| Shares Out (Mil) | 65.40 |
| Float (Mil) | 51.12 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 10.00 |
| Current Ratio | 10.70 |
| LT Debt/ Equity | 1.53 |
| Total Debt / Equity | 1.53 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 24.87 |
| Price/Book | 4.47 |
| Price/Cash Flow | -4.20 |
| Per Share Data | |
| Earnings | -2.73 |
| Sales | 0.43 |
| Book Value | 2.40 |
| Cash Flow | -2.55 |
| Business Summary | |
|---|---|
| InterMune, Inc. is a biotech company, which is focused on developing and commercializing innovative therapies in pulmonology and hepatology. | |
| General Information | |
| 3280 Bayshore Boulevrad
Brisbane, CA 94005 |
|
| www.intermune.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 206 | |
| CEO: Daniel G. Welch | |
| Short Interest | |
| Current Month (Mil) | 13.22 |
| Previous Month (Mil) | 12.48 |
| Short Interest Ratio (Days) | 6.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -38.90 |
| Return on Investments | -42.00 |
| Profitability | |
| Gross Margin | 75.50 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,454.83 | 1,317.82 | 2,837.53 | 17.45 |
Oil *
107.26
|
|
DOWN
74.92 |
DOWN
2.86 |
DOWN
1.85 |
DOWN
0.14 |
10 Yr
1.74%
SPDR Gold
152.68
|
|
-0.60%
|
-0.22%
|
-0.07%
|
-0.80%
|
Data delayed 20 minutes |
Connect with TheStreet